IL188317A0 - Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody - Google Patents

Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Info

Publication number
IL188317A0
IL188317A0 IL188317A IL18831707A IL188317A0 IL 188317 A0 IL188317 A0 IL 188317A0 IL 188317 A IL188317 A IL 188317A IL 18831707 A IL18831707 A IL 18831707A IL 188317 A0 IL188317 A0 IL 188317A0
Authority
IL
Israel
Prior art keywords
absence
detection
target antigen
therapeutic antibody
corresponding therapeutic
Prior art date
Application number
IL188317A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL188317A0 publication Critical patent/IL188317A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL188317A 2005-07-06 2007-12-20 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody IL188317A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (1)

Publication Number Publication Date
IL188317A0 true IL188317A0 (en) 2008-04-13

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
IL188317A IL188317A0 (en) 2005-07-06 2007-12-20 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Country Status (19)

Country Link
US (1) US20070009976A1 (enExample)
EP (2) EP2194380A3 (enExample)
JP (1) JP2008545145A (enExample)
KR (1) KR20080016939A (enExample)
AR (1) AR053948A1 (enExample)
AU (1) AU2006265275A1 (enExample)
BR (1) BRPI0612591A2 (enExample)
CA (1) CA2613187A1 (enExample)
CR (1) CR9635A (enExample)
EC (1) ECSP088081A (enExample)
IL (1) IL188317A0 (enExample)
MA (1) MA29730B1 (enExample)
MX (1) MX2008000277A (enExample)
MY (1) MY157955A (enExample)
NO (1) NO20076662L (enExample)
NZ (1) NZ564471A (enExample)
RU (1) RU2008103608A (enExample)
TW (1) TWI312864B (enExample)
WO (1) WO2007003420A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522444A (en) * 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
SI1771482T1 (sl) * 2004-07-22 2014-12-31 Genentech, Inc. Sestavek HER2 protitelesa
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
KR101134208B1 (ko) 2004-10-01 2012-04-09 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 촬상 장치 및 그 방법
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
NZ590431A (en) 2005-02-23 2012-08-31 Genentech Inc Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CN101680897B (zh) 2007-03-02 2013-11-13 健泰科生物技术公司 基于低her3表达预测对her二聚化抑制剂的响应
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MX2014004021A (es) 2011-10-14 2014-04-30 Genentech Inc Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
SG11201608912VA (en) 2014-04-25 2016-11-29 Genentech Inc Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
RS65871B1 (sr) 2015-05-30 2024-09-30 Hoffmann La Roche Postupci lečenja her2-pozitivnog prethodno nelečenog metastatskog karcinoma dojke
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
TWI729259B (zh) 2017-01-17 2021-06-01 美商建南德克公司 皮下her2 抗體調配物
CN114984206A (zh) 2017-03-02 2022-09-02 基因泰克公司 Her2阳性乳腺癌的辅助治疗
TW201902509A (zh) 2017-04-24 2019-01-16 美商建南德克公司 Erbb2/her2突變
KR20230030621A (ko) 2020-06-29 2023-03-06 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
IL129354A0 (en) 1996-10-18 2000-02-17 Genentech Inc Anti-ErbB2 antibodies
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)

Also Published As

Publication number Publication date
EP2194380A3 (en) 2010-07-14
EP2194380A2 (en) 2010-06-09
CA2613187A1 (en) 2007-01-11
US20070009976A1 (en) 2007-01-11
AR053948A1 (es) 2007-05-23
TW200741203A (en) 2007-11-01
MA29730B1 (fr) 2008-09-01
EP1902315A1 (en) 2008-03-26
RU2008103608A (ru) 2009-08-20
AU2006265275A1 (en) 2007-01-11
KR20080016939A (ko) 2008-02-22
NZ564471A (en) 2010-04-30
CR9635A (es) 2008-02-20
MY157955A (en) 2016-08-30
JP2008545145A (ja) 2008-12-11
TWI312864B (en) 2009-08-01
BRPI0612591A2 (pt) 2010-11-23
NO20076662L (no) 2008-04-03
WO2007003420A1 (en) 2007-01-11
MX2008000277A (es) 2008-03-24
ECSP088081A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
IL188317A0 (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
IL178823A0 (en) Platelet biomarkers for the detection of disease
IL227753A0 (en) A qualified antibody or antibody residue
IL189542A0 (en) Proteolysis resistant antibody preparations
EP2383297B8 (en) Optimized antibodies that target CD19
IL192604A0 (en) Anti-drug antibody assay
IL235620A0 (en) sp35 antibodies and their uses
SG10201404801YA (en) Monoclonal antibody
PL1964852T3 (pl) Przeciwciało anty-ilt7
PL1766017T3 (pl) Przeciwciało specyficzne wobec nowotworu
DE602005014679D1 (de) Zieldetektionseinrichtung
IL180789A0 (en) Human monoclonal antibodies against human il-4
EP1825295A4 (en) REINFORCED DETECTION SYSTEM OF A TARGET
FI20075251A0 (fi) Immunomääritys epästabiilien antigeenien määrittämiseksi
IL185781A0 (en) Antibodies against candida antigens
EP1958341A4 (en) ECHO DETECTION
GB0525541D0 (en) Detection of antibodies
EP2184605A4 (en) DUAL RECOGNITION IMMUNOASSAY FOR DETECTION OF ANTIBODIES
ZA200800083B (en) Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
ZA200707838B (en) Antibodies against Candida antigens
GB0412410D0 (en) Protein detection
PL2010652T3 (pl) Białko, przeciwciało i pomiar białka
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB2424981B (en) System for detecting the presence of an intruding body
FR2910896B1 (fr) Anticorps monoclonal dirige contre le recepteur humain des ldl